• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 27, 2021

View Archived Issues
Pregnancy

Obseva could bring in up to $500M in Organon deal for preterm labor drug

Organon & Co. will license exclusive global development, manufacturing and commercial rights to ebopiprant (OBE-022) from Obseva SA. Ebopiprant is a prostaglandin F2α receptor antagonist being developed for treating preterm labor by reducing inflammation and uterine contractions. Obseva could receive tiered double-digit royalties on commercial sales and as much as $500 million in up-front and milestone payments, including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million in sales-based milestones. Read More

Infinity shares fall following phase II eganelisib readouts

New data on the addition of Infinity Pharmaceuticals Inc.'s oral PI3K-gamma inhibitor, eganelisib, to PD-(L)1 in both urothelial and triple-negative breast cancer patients appeared to evidence benefits for the combination. Benefit for company shares (NASDAQ:INFI), however, was nowhere to be seen, as they fell 31.5% to $1.52 on July 27. In a same-day earnings report, the Cambridge, Mass.-based company said it had a cash balance of $97.3 million to fund further development of the drug and filed to raise the maximum amount of capital it may raise in future sales of its shares. Read More
DNA-analysis-diagnostic-research.png

Artios’ $153M series C to expand DDR platform beyond synthetic lethality

LONDON – Artios Ltd. has closed a $153 million series C, positioning it to intensify clinical development of its two lead programs, whilst applying its DNA damage response platform to exploit the full spectrum of vulnerabilities presented by inhibition of DNA damage repair enzymes. Read More
australia-coronavirus-covid-19.png

TGA looks to expand international collaboration in wake of COVID-19 isolation

PERTH, Australia – Australia was one of the first nations to slam its borders shut during the pandemic, praising its efforts in containing COVID-19 infections. Read More
Digital yuan illustration

Hongyun closes $15.5M series B to develop new-generation EGFR inhibitor

Hongyun Biotech Co. Ltd. raised ¥100 million (US$15.5 million) in a series B round to move its new generation EGFR inhibitor, RC-01, to the IND stage in China and the U.S. for non-small-cell lung carcinoma (NSCLC). The plan is to finish the IND filing by the end of this year and start the trial in 2022. Read More
stem-cells

Hopstem targeting stroke with iPSC-derived human forebrain neural progenitor cell product

With a special interest in neurological disorders, Hopstem Biotechnology Co. Ltd. closed a series A++ round to raise nearly ¥100 million (US$15.5 million) to advance hNPC-01, an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product to treat chronic conditions caused by stroke and traumatic brain injuries. Read More

Appointments and advancements for July 27, 2021

New hires and promotions in the biopharma industry, including: Capricor, Centogene, Etherna, Eyegate, Hummingbird, Immunomet, Lava, Lumos, Poseida, Prokarium, Springworks, Synox. Read More

Financings for July 27, 2021

Biopharmas raising money in public or private financings, including: Absci, AC Immune, BMS, Candel, Iggenix, Imago and Imidomics. Read More

In the clinic for July 27, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Allegro Ophthalmics, Cassava, Da Volterra, GNT, Inmune, Iveric, Lee's, Radius, Sorrento, Synaptogenix, Tarsus, Tonix, Virios. Read More

Other news to note for July 27, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Abuse Deterrent, AC, Acura, Adagio, Affiris, Astrazeneca, Biocon, Brainstorm, Bridgebio, Bristol, Byondis, Calico, Deargen, Glycotope, Ionctura, Regeneration. Read More

Regulatory actions for July 27, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aadi, Abbvie, Alexion, Astrazeneca, Beigene, Beximco, Eledon, Fidia, GSK, Incyte, Inhibikase, Iterum, Kyowa Kirin, Neoimmunetech, Otsuka, Polarityte, Saniona. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe